GSK, Theravance’s Breo Faces Scrutiny Over Safety for Asthma – Bloomberg


Reuters

GSK, Theravance's Breo Faces Scrutiny Over Safety for Asthma
Bloomberg
(Bloomberg) — GlaxoSmithKline Plc and Theravance Inc.'s respiratory drug Breo Ellipta will face questions from a regulatory panel over the safety of expanding its use to treat asthma patients and whether it's suitable for children. Advisers to the U.S
FDA staff finds no new safety problems with Glaxo's asthma drugReuters
GSK Studies Found No Asthma Deaths For COPD Drug, FDA SaysLaw360 (subscription)
New Glaxo asthma treatment reviewed by FDANational Monitor

all 25 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.